

Form 1449*	Atty. Docket No.: 295.044US1	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Alan R. Fritzberg et al.	
	Filing Date: June 12, 2000	Group: Unknown



## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AF	3,965,254	06/22/1976	Tofe et al.	424	1	11/15/74

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
AF	2 230 374	12/20/1974	France	A61K	27/04	Abstract Only
AF	91/16075	10/31/1991	PCT	A61K	43/00	

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
AF	Bayouth et al., "Pharmacokinetics, Dosimetry and Toxicity of Homium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma", <u>The Journal of Nuclear Medicine</u> , <u>36</u> , 730-737 (1995). ✓
AF	Bayouth et al., "Radiation Dose Distribution within the Bone Marrow of Patients Receiving Holmium-166-Labeled-Phosphonate for Marrow Ablation", <u>Medical Physics</u> , <u>22</u> , 743-753 (1995). ✓
AF	Champlin et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate For Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Blood</u> , <u>82</u> , Abstracts, American Society of Hematology Thirty-Fifth Annual Meeting, St. Louis, Missouri, USA, Abstract No. 1051, page 266a (1993). ✓
AF	Hassfjell et al., " <sup>212</sup> Bi-DOTMP: An Alpha Particle Emitting Bone-Seeking Agent for Targeted Radiotherapy", <u>Nuclear Medicine and Biology</u> , <u>24</u> , 231-237 (1997). ✓
AF	Kasi et al., "Ho-166DOTMP: A New Agent for Bone Marrow Ablation", <u>The Journal of Nuclear Medicine</u> , <u>34</u> , Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 125, page 33P (1993). ✓
AF	McCullough et al., "Non-Target Organ Doses in Patients Undergoing Bone Marrow Ablation with Ho-166-DOTMP", <u>The Journal of Nuclear Medicine</u> , <u>39</u> , Abstract Book, Scientific Abstracts of the 45th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada, Abstract No. 838, page 186P (1998). ✓

Examiner

R Jones

Date Considered

4/1/03

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.044US1	Serial No. <del>Unknown</del> 10/014335
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Alan R. Fritzberg et al.	
	Filing Date: June 12, 2000	Group: <del>Unknown</del> 10/6

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

W	McCullough et al., "Pharmacokinetics and Patient Specific Dosimetry of High Dose <sup>166</sup> Ho-DOTMP Therapy Used for Treatment of Breast Cancer Metastatic to Bone", <u>The Journal of Nuclear Medicine</u> , 40, 46 <sup>th</sup> Annual Meeting of the Society of Nuclear Medicine, Los Angeles, California, USA, Abstract No. 160, page 40P (1999).	X
	Parks et al., "Bone Marrow Transplantation in Dogs After Radio-Ablation with a New Ho-166 Amino Phosphonic Acid Bone-Seeking Agent (DOTMP)", <u>Blood</u> , 82, 318-325 (1993).	X
	Podoloff et al., "Phase I/II Study of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma Prior to Bone Marrow Transplantation (BMT)", <u>The Journal of Nuclear Medicine</u> , 35, Abstract Book, Proceedings of the 41st Annual Meeting of the Society of Nuclear Medicine, Orlando, Florida, USA, Abstract No. 139, page 37P (1994).	X
	Podoloff et al., "Update on the Ho-166 DOTMP Bone Marrow Ablation Trial at U.T.M.D. Anderson Cancer Center", <u>The Journal of Nuclear Medicine</u> , 37, Supplement: Radiolabeled IUdr, 43 <sup>rd</sup> Annual Meeting of the Society of Nuclear Medicine, Denver, Colorado, USA, Abstract No. 1053, page 234P (1996).	
	Turner et al., "Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment with Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation", <u>Journal of the National Cancer Institute</u> , 85, 1508-1513 (1993).	X
	Turner et al., "Samarium-153 EDTMP and Melphalan Chemoradiotherapy Regimen for Bone Marrow Ablation Prior to Marrow Transplantation in the C57BL/KaLwRij Mouse as a Model for Treatment of Multiple Myeloma", <u>Australian and New Zealand Journal of Medicine</u> , 22, 23 <sup>rd</sup> Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine, Adelaide, South Australia, Australia, 405 (1992).	X
W	Turner et al., " <sup>153</sup> Samarium EDTMP and Melphalan Chemoradiotherapy Regimen for Bone Marrow Ablation Prior to Marrow Transplantation: An Experimental Model in the Rat", <u>Nuclear Medicine Communications</u> , 13, 321-329 (1992).	X

Examiner

R. James

Date Considered


4/1/03

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 11

Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1614
Examiner Name	Spear, James D. Jove

Attorney Docket No: 00295.044US1

TECH CENTER 160012900

OCT 25 2002

RECEIVED

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
af	US-3,032,584	05/01/1962	Bergel, et al	260	518	03/12/1954
	US-3,032,585	05/01/1962	Bergel, et al	260	518	11/30/1955
	US-3,398,198	08/20/1968	Kersnar, et al	260	584	05/22/1967
	US-3,726,912	04/10/1973	McCrary, et al	260	513.N	07/02/1970
	US-3,852,414	12/03/1974	Adler, et al	424	1	09/13/1972
	US-3,931,396	01/06/1976	Bardy, et al	424	1	03/26/1974
	US-3,989,730	11/02/1976	Subramanian, et al	260	429.7	06/11/1973
	US-4,017,596	04/12/1977	Loberg, et al	424	1	09/02/1975
	US-4,058,704	11/15/1977	Shimizu	219	528	12/08/1975
	US-4,075,314	02/21/1978	Wolfangel, et al	424	1	04/29/1976
	US-4,104,366	08/01/1978	Schmidt-Dunker, et al	424	1	09/23/1976
	US-4,187,284	02/05/1980	Rolleston, et al	424	1	10/03/1977
	US-4,399,817	08/23/1983	Benedict	406	20	06/30/1981
	US-4,508,625	04/02/1985	Graham	210	695	10/06/1983
	US-4,515,767	05/07/1985	Simon, et al	424	1.1	06/20/1983
	US-4,560,548	12/24/1985	Simon, et al	424	1.1	04/10/1984
	US-4,606,907	08/19/1986	Simon, et al	424	1.1	07/02/1984
	US-4,639,365	01/27/1987	Sherry	424	9	10/18/1994
	US-4,647,447	03/03/1987	Gries, et al	424	9	01/23/1984
	US-4,678,667	07/07/1987	Meares, et al	424	85	07/02/1985
	US-4,752,464	06/21/1988	Lieberman, et al	424	1.1	06/07/1985
	US-4,808,541	02/28/1989	Mikola, et al	436	501	02/20/1987
	US-4,853,209	08/01/1989	Kaplan, et al	424	1.1	10/27/1987
	US-4,882,142	11/21/1989	Simon, et al	424	1.22	12/19/1988
	US-4,885,363	12/05/1989	Tweedle, et al	540	465	12/23/1987
	US-4,897,254	01/30/1990	Simon, et al	424	1.1	03/03/1987
	US-4,898,724	02/06/1990	Simon, et al	424	1.1	05/14/1987
	US-4,937,333	06/26/1990	Garlich, et al	540	474	08/04/1989
	US-4,957,939	09/18/1990	Gries, et al	514	492	06/20/1986
	US-4,976,950	12/11/1990	Simon, et al	424	1.1	11/13/1989
	US-5,059,412	10/22/1991	Simon, et al	424	1.1	12/19/1988
	US-5,064,633	11/12/1991	Simon, et al	424	1.1	12/19/1989
	US-5,066,478	11/19/1991	Simon, et al	424	1.1	01/30/1990
	US-5,286,497	02/15/1994	Hendrickson, et al	424	490	05/06/1993
	US-5,300,279	04/05/1994	Simon, et al	424	1.77	12/19/1990
	US-5,587,451	12/24/1996	Athey, et al	528	345	10/07/1994
	US-5,621,001	04/15/1997	Canetta, et al	514	449	11/20/1995
	US-5,641,803	06/24/1997	Canetta, et al	514	449	10/18/1995
	US-5,665,761	09/09/1997	Canetta, et al	514	449	11/22/1996
	US-5,670,537	09/23/1997	Canetta, et al	514	449	09/19/1996

EXAMINER

DATE CONSIDERED

4/2/03

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-16/16
Examiner Name	Spear, James D. <i>[Signature]</i>

Sheet 2 of 11

Attorney Docket No: 00295.044US1

TECH CENTER 1600/2900

OCT 25 2002

RECEIVED

US-5,707,610	01/13/1998	Ibsen, et al	424	049	05/30/1995
US-5,708,169	01/13/1998	Hester Jr., et al	549	152	09/05/1996
US-5,712,275	01/27/1998	Van Gestel	514	222.5	01/25/1996
US-5,714,467	02/03/1998	Boman, et al	514	012	03/26/1993
US-5,714,504	02/03/1998	Lindberg, et al	514	338	01/23/1995
US-5,714,604	02/03/1998	Kiefer	540	472	05/06/1993
US-5,756,472	05/26/1998	Liesch, et al	514	27	01/27/1997
US-5,756,505	05/26/1998	Nishino, et al	514	253	04/01/1996
US-5,756,725	05/26/1998	Wilkening, et al	540	302	04/08/1997
US-5,760,063	06/02/1998	Lam, et al	514	355	09/13/1996
US-5,762,907	06/09/1998	Simon, et al	424	1.77	10/07/1993
US-5,770,617	06/23/1998	LaVoie, et al	514	394	01/21/1997
US-5,773,421	06/30/1998	Alder, et al	514	025	12/21/1995
US-5,773,443	06/30/1998	Ray, et al	514	256	07/18/1996
US-5,773,696	06/30/1998	Liang, et al	800	205	03/29/1996
US-5,783,570	07/21/1998	Yokota, et al	514	056	12/23/1996
US-5,786,325	07/28/1998	Borromeo, et al	514	011	03/11/1996
US-5,801,172	09/01/1998	Clapp-Shapiro, et al	514	250	07/11/1997
US-5,807,854	09/15/1998	Bartoli, et al	514	248	03/21/1997
US-5,814,634	09/29/1998	Nishino, et al	514	237.8	04/17/1997
US-5,824,698	10/20/1998	Hasler, et al	514	394	05/14/1997
US-5,824,874	10/20/1998	Ulbrich, et al	800	205	07/29/1996
US-5,830,855	11/03/1998	Takemoto	514	011	09/12/1996
US-5,830,889	11/03/1998	Iwata, et al	514	195	02/19/1993
US-5,837,253	11/17/1998	Cohen	424	195.1	10/29/1996
US-5,837,726	11/17/1998	Liu, et al	514	475	11/01/1995
US-5,849,956	12/15/1998	Koga, et al	568	326	08/08/1997
US-5,854,213	12/29/1998	Bouffard	514	011	06/06/1997
US-5,854,280	12/29/1998	Gomez, et al	514	456	10/18/1996
US-5,856,347	01/05/1999	Hashiguchi, et al	514	390	05/23/1997
US-5,859,032	01/12/1999	Nishino, et al	514	352	03/17/1997
US-5,861,430	01/19/1999	Markonius	514	456	06/07/1995
US-5,863,773	01/26/1999	Gunawardana, et al	435	118	09/30/1997
US-5,866,549	02/02/1999	Or, et al	514	029	07/03/1997
US-5,872,249	02/16/1999	Park, et al	540	225	09/30/1997
US-5,876,738	03/02/1999	Ohno, et al	424	404	10/24/1997
US-5,888,526	03/30/1999	Tsubai, et al	424	405	04/03/1997
US-5,888,941	03/30/1999	Bartoli, et al	504	262	03/31/1997
US-5,891,890	04/06/1999	Nishino, et al	514	331	04/02/1998
US-5,908,862	06/01/1999	Wai Lee, et al	514	546	07/31/1996
US-5,910,498	06/08/1999	Yazaki, et al	514	255	07/08/1997
US-5,917,084	06/29/1999	Jiang	560	174	07/03/1996
US-5,919,438	07/06/1999	Saint-Leger	424	70.1	04/15/1997

EXAMINER

DATE CONSIDERED

4/12/03


Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 3 of 11

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number.

Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615 1616
Examiner Name	Spear, James D. Jones

Attorney Docket No: 00295.044US1

OCT 24 2002  
CH CENTER 1600/2900

RECEIVED

US-5,919,925	07/06/1999	Burton, et al	540	300	10/14/1997
US-6,241,961	06/05/2001	Benes, et al	424	1.49	03/26/1999

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
109	CA-1078731	06/03/1980	Rolleston, et al	A61K	29/00	
	EP-0164843	12/18/1985	Simon, et al	A61K	43/00	
	EP-0210043	01/28/1987	Sadler, et al	A61K	49/00	
	EP-0232751	08/19/1987	Tweedle, et al	C07D	273/00	
	EP-0255471	02/03/1988	Gries, et al	C07D	257/02	With English Abstract
	EP-0258616	03/09/1988	Kraft, et al	A61K	49/00	
	EP-0287465	10/19/1988	Schaeffer, et al	C07D	257/02	With English Abstract
	EP-0374501	06/27/1990	Simon, et al	A61K	43/00	
	EP-0382582	08/16/1990	Parker, et al	C07F	9/6524	
	EP-0408701	02/23/1991	Simon, et al	A61K	43/00	
	EP-0411941	02/06/1991	Garlich, et al	C07F	9/38	
	EP-0698029	02/28/1996	Kiefer	C07F	9/6524	
	EP-0972528	01/19/2000	Benes, et al	A61K	51/10	With English Abstract
	WO-84/03698	09/27/1984	Mikola, et al	C07C	161/04	
	WO-90/06776	06/28/1990	Simon, et al	A61K	43/00	
	WO-94/26753	11/24/1994	Kiefer	C07F	9/65	
109	WO-95/10940	04/27/1995	Jacobson, et al	A01N	59/16	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
109		"Bone Cancer Therapy Project Funding Awarded to Brookhaven National Laboratory for Diatide-Licensed Product", DISTRIBUTION: Business Editors and Health/Medical Writers, (June, 1999)	
109		"Breast Cancer; Genitourinary Cancer; Multiple Myeloma", Annotated Guide to Cancer Chemotherapeutic Regimens 1999/2000, Oncology Special Edition, 13-14; 17-18; 32	
109		"Chapter III: Chemotherapy Regimens in Adults", In Cancer Chemotherapy Pocket Guide, Robert J. Ignoffo, Editor, (1998), 248-255; 338-341	
109		"Letter to Odajima Patent Office from The Dow Chemical Company regarding Japanese Patent Application No. 525620/94, including pages 16-19 from WO 94/26753"	
109		"Letter to The Dow Chemical Company from A. Aoki and Associates regarding Japanese Patent Application No. 2-194121, including pages 23-25"	
109		"Letter to The Dow Chemical Company from Smart and Biggar confirming a request for examination regarding Canadian Patent Application Patent File No.:	

EXAMINER

DATE CONSIDERED

4/2/03


Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1618
Examiner Name	Spear, James D. Jms

Sheet 4 of 11

Attorney Docket No: 00295.044US1

RECEIVED  
 OCT 25 2002  
 PTO CENTER 1600 2800

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		2,020,950, accompanied by pages 23-25."	
		"Letter to The Dow Chemical Company from Smith and Biggar regarding Canadian Patent Application Patent File No.: 2162170, including pages 16-19 from WO 94/26753."	
		"Letter to the Dow Chemical Company from Smith and Biggar regarding retyped page Nos. 31-34 for Canadian Patent Application Serial No. 2,003,326."	
		"Letter to The Dow Chemical Company regarding Canadian Application Serial No. 2,005,880, including pages 41-45 of the claims."	
		"Multiple Myeloma", In <u>Clinical Oncology, A Multidisciplinary Approach for Physicians and Students</u> , 7th Edition, Philip Rubin, Editor, (1993), 239-244	
		"NeoRx Updates Skeletal Targeted Radiotherapy (STR) Phase I/II Trial Data", NeoRx Press Release, (May 7, 2001)	
		"NeoRx's Multiple Myeloma Study with Targeted Radiotherapy to be Updated at ASH -- Recent Thalidomide Results Heighten Interest in New Multiple Myeloma Therapies", NeoRx Press Release, (November 30, 1999)	
		"NeoRx's Skeletal Targeted Radiotherapy Slide Presentation", (August, 1999), 16 pages	
		"NeoRx's Targeted Radiotherapy Achieves Complete Responses with Excellent Safety in Multiple Myeloma Patients", NeoRx Press Release, (December 7, 1999), 2 pages	
		"Phase I/II Interim Data on NeoRx's STR Product in Multiple Myeloma", NeoRx Press Release, (1999), 2 pages	
		ABRAMS, PAUL, "High-Dose Targeted Radiation to Bone and Bone Metastases", CaP CURE Meeting, Lake Tahoe, NV, (September, 2000)	
		ALEXANIAN, R., et al., "Impact of Complete Remission with Intensive Therapy in Patients with Responsive Multiple Myeloma", <u>British Journal of Hematology</u> , 27(10), (2001), 1037-1043	
		ANDO, A., et al., "177Lu-EDTMP: A Potential Therapeutic Bone Agent", <u>Nucl. Med. Commun.</u> , 19(6), (June 1998), 587-591	
		APPELBAUM, F.R., et al., "Chronic and Acute Leukemias in Adults", <u>The Role of Marrow Transplantation in the Treatment of Leukemia</u> , Martinus Nijhoff Publishers, Boston. C.D. Bloomfield, editor, (1985), 229-262	
		APPELBAUM, F.R., et al., "Specific Marrow Ablation Before Marrow Transplantation Using an Aminophosphonic Acid Conjugate 166Ho-EDTMP", <u>Blood</u> , 80, (1992), 1608-1613	
		BARDIES, M., et al., "Computational Methods in Radionuclide Dosimetry", <u>Physics in Medicine and Biology</u> , 41, (1996), 1941-1955	
		BARLOGIE, B., et al., "Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.", <u>Blood</u> , 72, (1988), 2015-2019	
		BATAILLE, R., et al., "Multiple Myeloma", <u>New England Journal of Medicine</u> , 336, (1997), 1657-1664	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1616
Examiner Name	Spear, James D. Jones

Sheet 5 of 11

Attorney Docket No: 00295.044US1

**RECEIVED**  
 OCT 25 2002  
 CH CENTER 1600/2900

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BAYOUTH, J.E., et al., "Dosimetry Considerations of Bone-Seeking Radionuclides for Marrow Ablation", <u>Medical Physics</u> , 20, (1993), 1089-1096	
		BEARMAN, et al., "Regimen-Related Toxicity in Patients Undergoing Bone Marrow Transplantation", <u>Journal of Clinical Oncology</u> , 6, (1988), 1562-1568	
		BEDDOE, A.H., et al., "Measurements of Trabecular Bone Structure in Man", <u>Physics in Medicine and Biology</u> , 21, (1976), 589-607	
		BENSINGER, WILLIAM, et al., "166Holmium-DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM)", Abstract No. 3133, <u>Blood</u> , (1999), 709A	✓
		BENSINGER, B., et al., "166Holmium-DOTMP Plus Standard High Dose Chemotherapy (HDC) with Autologous Transplant Produce High Rates of Complete Remission (CR) in Multiple Myeloma (MM) Patients: An Updated Report of a Phase I/II Study", <u>Proceedings of the American Society of Clinical Oncology</u> , 20, Abstract No. 18, (2001), 5a	
		BENSINGER, W., et al., "Phase I/II Study of 166Holmium-DOTMP in Combination with Melphalan +/- Total Body Irradiation (TBI) with Autologous Peripheral Blood Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Proceedings of the American Society of Clinical Oncology</u> 2000, 19, Abstract No. 26, (2000), 9a	
		BIGLER, R., et al., "Skeletal Distribution of Mineralized Bone Tissue in Humans", <u>Health Physics</u> , 31, (1976), 213-218	
		BOUSSIOTIS, V.A., et al., "Bone Marrow Transplantation for Low-grade Lymphoma and Chronic Lymphocytic Leukemia", <u>Seminars in Hematology</u> 36, (1999), 209-216	
		BREITZ, H., "Dosimetry in a Myeloablative Setting", Annual Society of Nuclear Medicine Meeting, Continuing Education Course, (June, 2001), 22 pages	
		BREITZ, H., et al., "Dosimetry in Myeloblastic Setting", <u>Cancer Biother. Radiopharm.</u> , 17(1), (2002), 119-128	
		BREITZ, H., et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy with Ho-166 DOTMP", Presentation at VIIth International Radiopharmaceutical Dosimetry Symposium, (2002), 3 pages	
		BREITZ, H., et al., "Multiple Myeloma: Skeletal Targeted Radiotherapy with 166-Ho-DOTMP for Treatment of Multiple Myeloma", Presented at "Targeted Radionuclide Therapy", (March, 2002), 4 pages	
		BREITZ, H., "Quantitative Dosimetry Workup in a Myeloablative Setting", Presentation at the 48th Annual Society for Nuclear Medicine Meeting, (June, 2001), 45 pages	
		CHAMPLIN, R., et al., "166Holmium-DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM)", <u>Blood</u> ,	

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary.)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1616
Examiner Name	Spear, James D. Jones

TECH CENTER 1600/2900

OCT 25 2002

RECEIVED

Sheet 6 of 11

Attorney Docket No: 00295.044US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PG		94(10), American Society of Hematology, Abstract No. 3133, (October, 1999), 709a	
		CHAMPLIN, R., et al., "Bone Marrow Transplantation for Acute Leukemia: Recent Advances and Comparison with Alternative Therapies", <u>Seminars in Hematology</u> , 24, (1987), 55-67	
		CHAMPLIN, R., et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate for Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Experimental Hematology</u> , 21, Abstracts, 22nd Annual Meeting of the International Society for Experimental Hematology, Rotterdam, The Netherlands, Abstract No. 393, (1993), 1117	
		CHAMPLIN, R., et al., "Phase I/II Study of Targeted Radiotherapy Using 166Ho-DOTMP with Melphalan and Peripheral Blood Stem Cell Transplant for Multiple Myeloma", A slide presentation, International Society of Experimental Hematology, (2000), 19 pages	
		CHAMPLIN, R., et al., "Role of Bone Marrow Transplantation in the Treatment of Hematologic Malignancies and Solid Tumors: Critical Review of Syngeneic, Autologous, and Allogeneic Transplants", <u>Cancer Treatment Reports</u> , 68, (1984), 145-161	
		CHAMPLIN, R., et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with Melphalan With or Without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Experimental Hematology</u> , 27(7), Abstract No. 196, Program and Abstracts, 28th Annual Meeting of the International Society for Experimental Hematology, Monte Carlo, Monaco, (July, 1999), 88	
		CUNNINGHAM, D., et al., "High-Dose Melphalan for Multiple Myeloma: Long-term Follow-up Data", <u>Journal of Clinical Oncology</u> , 12, (1994), 764-768	
		DURRANT, SIMON, et al., "Sm-153 Lexitronam, Limb Irradiation and Stem Cell Transplantation for the Treatment of Multiple Myeloma", Amer. Soc. Hemeotology Annual Meeting, Orlando, FL., (2001), 1 page	
		EARY, JANET, F., et al., "Samarium-153-EDTMP Biodistribution and Dosimetry Estimation", <u>The Journal of Nuclear Medicine</u> , 34, (1993), 1031-1036	
		ECKERMAN, K., et al., "Dose Conversion Factors for Marrow and Bone by Skeletal Regions", <u>Journal of Nucler Medicine</u> , 35, Abstract No. 445, (1994), 112P	
		EISENHUT, M., "Iodine-131-Labeled Diphosphonates for the Palliative Treatment of Bone Metastases: I. Organ Distribution and Kinetics of I-131 BDP3 in Rats", <u>The Journal of Nuclear Medicine</u> , 25, (1984), 1356-1361	
PG		FIRUSIAN, N., et al., "Results of 89Strontium Therapy in Patients with Carcinoma of the Prostate and Incurable Pain from Bone Metastases: A Preliminary Report", <u>The Journal of Urology</u> , 116, (1976), 764-768	
PG		FRITZBERG, ALAN, "166Ho-DOTMP: Skeletal Targeting Radiotherapeutic	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1616
Examiner Name	Spear, James D. Jones



Sheet 7 of 11

Attorney Docket No: 00295.044US1

RECEIVED  
OCT 25 2002  
TECH CENTER 1600/2900

RECEIVED

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
		Agent for Bone Marrow Ablation and Treatment of Bone and Bone Marrow-Based Cancers", <u>Slide Presentation</u> , (June, 1999), 17 pages		
		FRITZBERG, ALAN.R. , "Holmium-166 DOTMP for Marrow Ablation: Clinical Studies to Demonstrate Efficacy in Multiple Myeloma", Society of Nuclear Medicine Annual Meeting, St. Louis, (June, 2000), 4 pages		
		GARLICH, J.R., et al., "Chemical Considerations of 153Sm-EDTMP, a New Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 140, (1986), 317-319		
		GARLICH, J. R., et al., "Chemistry of Novel Macrocyclic Aminophosphonic Acid Chelates of Rare Earth Radionuclides and Their in vivo Biodistribution", <u>The Journal of Nuclear Medicine</u> , 34, Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 1134, (1993), 244P		
		GERALDES, C.F., et al., "Synthesis, Protonation Sequence, and NMR Studies of Polyazamacrocyclic Methylenephosphonates", <u>Inorganic Chemistry</u> , 28, (1989), 3336-3341		
		GIRALT, S., et al., "Hemorrhagic Cystitis after Targeted Radiotherapy with Holmium-DOTMP (166HO) for Multiple Myeloma (MM) is Preventable with Bladder Irrigation", <u>Blood</u> , 96(11), Abstract No. 1686, (2000), 1 page		
		GIRALT, S., et al., "Preliminary Results of a Phase I/II Study of Multiple Myeloma (MM) Patients Treated with 166Holmium-DOTMP in Combination with High Dose Melphalan +/- Total Body Irradiation (TBI) with Autologous Stem Cell Transplant (ASCT)", <u>Blood</u> , 96(11), Abstract No. 2395, (2000), 1 page		
		GIRALT, S., et al., "Results of a Phase I/II Trial with 166Ho-DOTMP Plus High Dose Chemotherapy in Patients with Multiple Myeloma", <u>VIIIth Int'l Multiple Myeloma Proceedings</u> , Abstract No. S24, (2001), 40-41		
		GIRALT, S., et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with or without TBI as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>VIIth Int'l Multiple Myeloma Proceedings</u> , Abstract No. 033, (1999), 117		
		GOECKELER, W.F., et al., "Samarium-153 Radiotherapeutic Bone Agents", <u>Nucl. Med. Biol.</u> , 13, (1986), 479-482		
		HSIA, C.,et al. , "Preparation of 113mIn-DTPMP Bone Scanning Agent and its Preliminary Clinical Application", <u>Chemical Abstracts</u> , 95, (1981), 305		
		JOHN, E.K., et al., "Formulation Development and Stability of the 166Ho-DOTMP for High Level Dosages - A Skeletal Targeted Radiotherapeutic", <u>Journal of Nuclear Medicine</u> , 42, Proceedings of the SNM 48th Annual Meeting, No. 1122, (2001), 267P		
			KABACHNIK, M.I., et al., "Synthesis and Study of a New Complexone - N,N',N'' - Tris-(Dihydroxyphosphorylmethyl) - 1,4,7 - Triazacyclononane", <u>Bulletin of the Academy of Sciences of the USSR; Division of Chemical Science</u> , 33, (1984),	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1446)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1616
Examiner Name	Spear, James D. Jones

Sheet 8 of 11

Attorney Docket No: 00295.044US1

RECEIVED  
 OCT 25 2002  
 TECH CENTER 1600/2900

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PG		769-777	
		KEELING, A.A., et al., "Yttrium-90-EDTMP: A Radiotherapeutic Agent in the Treatment of Leukaemias", <u>British Journal of Cancer</u> , 60, (1989), 74-78	
		KETRING, A.R., "153Sm-EDTMP and 186Re-HEDP as Bone Therapeutic Radiopharmaceuticals", <u>Nucl. Med. Biol.</u> , 14(3), (1987), 223-232	
		KOHN, D.B., "The Current Status of Gene Therapy Using Hematopoietic Stem Cells", <u>Current Opinion in Pediatr.</u> , 7, (1995), 56-63	
		KOTHARI, K.K., et al., "186RE and 188RE Phosphonate Ligands", <u>The Journal of Nuclear Medicine</u> , 40, Proceedings of the 46th Annual Meeting, Abstract No. 1015, (1999), 228P	
		KRISHNAMURTHY, G.T., et al., "Tin-117m(4+)DTPA: Pharmacokinetics and Imaging Characteristics in Patients with Metastatic Bone Pain", <u>The Journal of Nuclear Medicine</u> , 38, (1997), 230-237	
		KRIVIT, W., et al., "Bone Marrow Transplantation as Effective Treatment of Central Nervous System Disease in Globoid Cell Leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III", <u>Curr Opin Neurol</u> , 12(2), (April 1999), 167-176	
		LOGAN, K.W., et al., "Radiation Dose Calculations in Persons Receiving Injection of Samarium-153-EDTMP", <u>J. Nucl. Med.</u> , 28, (1987), 505-509	
		MA, J., et al., "Indium-113m Labeled Bone Imaging Agents - Animal Experiment and Clinical Application of 113mIn-DTPMP and 113mIn-EDTMP", <u>Chemical Abstracts</u> , 93, (1980), 285	
		MATHIEU, L., et al., "Preparation of Rhenium-186 Labelled EHDP and its Possible Use in the Treatment of Osseous Neoplasms", <u>International Journal of Applied Radiation and Isotopes</u> , 30, (1979), 725-727	
		MCCULLOUGH, S.P., et al., "99mTc-MDP as a Surrogate Quantitative Imaging Agent for High Dose 166Ho-DOTMP Bone Marrow Ablation Therapy", <u>Society of Nuclear Medicine Proceedings of the 47th Annual Meeting</u> , 41(5), Abstract No. 580, (2000), 147P	
		MCCULLOUGH, S.P., et al., "Preliminary Correlation of Bone Marrow Dose Distributions and Disease Response in Multiple Myeloma Patients Treated with Target Skeletal Radiotherapy", <u>The Journal of Nuclear Medicine, Proceedings of the 47th Annual Meeting</u> , 41(5), Abstract No. 327, (2000), 83P	
		MOREAU, P., et al., "Melphalan 220 mg/m2 Followed by Peripheral Blood Stem Cell Transplantation in 27 Patients with Advanced Multiple Myeloma", <u>Bone Marrow Transplant</u> , 23(10), (May, 1999), 1003-1006	
		NAIL, S.L., "The Relationship Between the Structure of Aluminum Hydride Gel and Acid Reactivity", <u>Chemical Abstracts</u> , 84, (1976), 353	
		O'MARA, R.E., et al., "Rare Earth Nuclides as Potential Agents for Skeletal	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number 10/014335

Filing Date December 11, 2001

First Named Inventor Fritzberg, Alan

Group Art Unit 1615-1616

Examiner Name Spear, James D. Jones

Sheet 9 of 11

Attorney Docket No: 00295.044US1

RECEIVED  
 OCT 25 2002  
 PATENT CENTER 1600 2900

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Imaging", <u>The Journal of Nuclear Medicine</u> , 10, (1969), 49-51	
		PAULSON, TOM, "Seattle Leads in Stem Cell Study: Fred Hutchinson Team Explores Options with Autoimmune Project", <u>The Seattle Post-Intelligencer</u> , (June 5, 1999), 1 page	
		PODOLOFF, D.A., et al., "Phase I/II Studies of Holmium-166 DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen For Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma (MM)", <u>European Journal of Nuclear Medicine</u> , Abstract No. PS-641, 1213	
		PODOLOFF, DONALD. A., "The Role of Radioisotopes and the Treatment of Solid Tumors", <u>Accomplishments with Medical Isotopes: Advanced Health Care for the 21st Century</u> , Medical Isotopes and the 21st Century, (March 10-13, 1999), 1 page	
		RAJENDRAN, J.G., et al., "High Dose Holmium-166 DOTMP Myeloablative Treatment for Multiple Myeloma", <u>Journal of Nuclear Medicine</u> , Proceedings of the 47th Annual Meeting, Abstract No. 576, (2000), 146P	
		RAJENDRAN, J.G., et al., "Holmium-166 DOTMP: An Agent with Ideal Physical and Pharmacokinetic Characteristics for Use in Myeloablative Treatment of Multiple Myeloma", <u>Western Regional Soc. Nucl. Med.</u> , (2000), 1 page	
		ROSCH, F., et al., "Radiation Doses of Yttrium-90 Citrate and Yttrium-90 EDTMP as Determined via Analogous Yttrium-86 Complexes and Positron Emission Tomography", <u>European Journal of Nuclear Medicine</u> , 23, (August, 1996), 958-966	
		ROSOFF, B., et al., "Distribution and Excretion of Radioactive Rare-Earth Compounds in Mice", <u>International Journal of Applied Radiation and Isotopes</u> , 14, (1962), 129-135	
		SALTUS, RICHARD, "Double Transplant's Success May Lead to End of Rejection Drugs", <u>The Seattle Post-Intelligencer</u> , (August, 1999), 1 page	
		SHERRY, A.D., "31P and 23Na NMR Lanthanide Induced Shifts in Axially Symmetric Macrocyclic Phosphonate Complexes", <u>Inorganica Chimica Acta</u> , 139, (1987), 137-139	
		SHERRY, A.D., et al., "Dy(DOTP)5-: A New, Stable, 23Na Shift Reagent", <u>Journal of Magnetic Resonance</u> , 76, (1988), 528-533	
		SHIBATA, Y., et al., "Selectively Eliminated Blood Monocytes and Splenic Suppressor Macrophages in Mice Depleted of Bone Marrow by Strontium 89", <u>J. Leukocyte Biol.</u> , 38, (1985), 659-669	
		SIMON, J., et al., "153Sm-EDTMP, a Potential Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 141, (1986), 320-322	
		SPIERS, F.W., et al., "Mean Skeletal Dose Factors for Beta-particle Emitters in Human Bone. Part II: Surface-seeking Radionuclides", <u>British Journal of</u>	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1616
Examiner Name	Spear, James D. Jones

Sheet 10 of 11

Attorney Docket No: 00295.044US1

RECEIVED  
OCT 25 2002  
ECH CENTER 1600/2900

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>[Signature]</i>		Radiology, 54, (1981), 500-504	
		SRIVASTAVA, S.C., et al., "10Ruthenium-97 Labeled Compounds - A New Class of Radiopharmaceuticals", Medical Department, Brookhaven National Laboratory, Upton, NY 11973, 123-133	
		STABIN, M.G., et al., "Bremsstrahlung Radiation Dose in Yttrium-90 Therapy Applications", J Nucl Med, 35, (1994), 1377-1380	
		SUBRAMANIAN, G., et al., "Indium-113m Labeled Polyfunctional Phosphonates as Bone Imaging Agents", Chemical Abstracts, 87, (1977), 243	
		SUBRAMANIAN, G., et al., "Indium-113m-Labeled Polyfunctional Phosphonates as Bone-Imaging Agents", Journal of Nuclear Medicine, 16, (1975), 1080-1084	
		SUBRAMANIAN, G., et al., "Localization of new Tc-99m Labeled Diphosphonates in Experimental Bone Lesions", Presented at the 19th International Annual Meeting of the Society of Nuclear Medicine Europe, Bern, Switzerland, September 8-11, 1981, (1981), 7 pages	
		SWAILEM, FAYEZ, et al., "In vivo Tissue Uptake and Retention of Sn-117m(4+)DTPA in a Human Subject with Metastatic Bone Pain and in Normal Mice", Nuclear Medicine & Biology, 25, (1988), 279-287	
		TANANAEV, I.V., et al., "Lanthanide Ethylenediametetramethylphosphonates", Chemical Abstracts, 96, (1982), 553	
		THOMAS, E.D., "Clinical Trials with Bone Marrow Transplantation", Clinical Trials in Cancer Medicine, Academic Press, Inc., (1985), 239-253	
		THOMAS, E.D., "Marrow Transplantation for Malignant Diseases", Journal of Clinical Oncology, 1, (1983), 517-531	
		THOMAS, E.D., et al., "Marrow Transplantation for Thalassemia", Annals New York Academy of Sciences, 445, (1985), 417-427	
		THOMAS, S.R., "MIRD Pamphlet No. 14: A Dynamic Urinary Bladder Model for Radiation Dose Calculations", Journal of Nuclear Medicine, 33, Published erratum appears in Journal of Nuclear Medicine, 35, 73 (1994), (1992), 783-802	
		VOLKERT, W.A., et al., "Characteristics of Tc-99m-Complexes of Large Tetraphosphonates", 1984 Abstract Form for Scientific Exhibits Society of Nuclear Medicine 31st Annual Meeting, Los Angeles, California, June 5-8, 1984, 1 page	
		WEININGER, J., "Re-186 HEDP: A Potential Therapeutic Bone Agent", 24(5), Proceedings of the 30th Annual Meeting - Posters, P125	
		WENDT, R.E., "An Improved Estimate of Activity in Skull-Like Structures", Journal of Nuclear Medicine, 42, Abstract No. 830, Proceedings of the 48th Annual Meeting, (2001), 193P	
		WENDT, R.E., et al., "Correction of Scatter and Septal Penetration in Ho-166 Images to Enable Narrow Beam Attenuation Correction", Journal of Nuclear medicine, 43(5), (May, 2002), 221P-222P	
		WINSTON, M.A., "Radioisotope Therapy in Bone and Joint Disease", Seminars	

EXAMINER

DATE CONSIDERED


Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615-1616
Examiner Name	Spear, James D. Jones

RECEIVED  
OCT 25 2002  
PCH CENTER 1600/2900

Sheet 11 of 11

Attorney Docket No: 00295.044US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>[Signature]</i>		in Nuclear Medicine, 9, (1979), 114-120	
<i>[Signature]</i>		YOUNG, J.C., et al., "High Dose Samarium-153 Ethylenediaminetetramethylene Phosphate (SM-153 EDTMP) in the Treatment of Bone Sarcomas", <u>The Journal of Nuclear Medicine</u> , 40(5), Proceedings of the 46th Annual Meeting, (May 1999), Abstract No. 977, 219P	
<i>[Signature]</i>		ZEEVAART, JAN. R., et al., "Metal-ion Speciation in Blood Plasma Incorporating the Bisphosphonate, 1-hydroxy-4-aminopropylidenediphosphonate (APD), in Therapeutic Radiopharmaceuticals", <u>Journal of Inorganic Biochemistry</u> , 73, (1999), 265-272	

EXAMINER

DATE CONSIDERED

4/2/83

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached